Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05869773 · ClinicalTrials.gov registry record · Phase 4

A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

A Phase 4 study of Narcolepsy, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
160
Enrollment target
20
Study locations

NCT05869773 is a Phase 4 study of Narcolepsy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 160 participants, below the 367-participant average among 12 other Narcolepsy trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05869773, a Phase 4 study of Narcolepsy, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.

Conditions Studied

Narcolepsy

Interventions

  • DRUG JZP258

Study Locations (20)

California

  • Science 37 - Culver City
  • M3 Wake Research - Encino
  • So Cal Clinical Research - Huntington Beach
  • Long Beach Research Institute - Lakewood
  • Stanford School of Medicine - Redwood City
  • TriValley Sleep Center - San Ramon
  • SDS Clinical Trials, Inc. - Santa Ana

Florida

  • FWD Clinical Research - Boca Raton
  • Meris Clinical Research, LLC - Brandon
  • Ocean Wellness Center - Miami
  • Serenity Research Center LLC - Miami
  • Florida Pediatric Research Institute, LLC - Orlando

Georgia

  • Sleep Practitioners, LLC - Macon

Idaho

  • Saltzer Medical Group - Nampa

Kentucky

  • University of Louisville - Louisville

Maryland

  • University of Maryland Medical Center - Baltimore

Massachusetts

  • Neurocare, Inc - Newton

Michigan

  • Sparrow Health System - Lansing

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2023-06-26
Est. Completion 2025-03-10
Phase Phase 4

Sponsor

Jazz Pharmaceuticals

128 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05869773

The ClinicalTrials.gov registry entry for NCT05869773 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 12 other Narcolepsy trials with a reported enrollment target (56% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 1 intervention - of which JZP258 is the first listed.

NCT05869773 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05869773 about?

NCT05869773 is a clinical study titled "A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy". The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new informatio...

What is the current status of trial NCT05869773?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2023-06-26. Estimated completion is 2025-03-10.

What conditions does trial NCT05869773 study?

This clinical trial studies the following conditions: Narcolepsy.

What interventions are being tested in trial NCT05869773?

The interventions under investigation include: JZP258 (DRUG).

Who is sponsoring clinical trial NCT05869773?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05869773 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Idaho, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Narcolepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Narcolepsy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.